Transcend Capital Advisors LLC Boosts Holdings in Zoetis Inc. (NYSE:ZTS)



Transcend Capital Advisors LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) by 8.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,665 shares of the company’s stock after acquiring an additional 129 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Zoetis were worth $314,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. BlackRock Inc. increased its holdings in Zoetis by 3.7% during the 4th quarter. BlackRock Inc. Now owns 40,315,810 shares of the company’s stock valued at $9,838,266,000 after acquiring an additional 1,427,812 shares in the last quarter. State Street Corp increased its holdings in Zoetis by 2.7% during the 4th quarter. State Street Corp now owns 19,994,627 shares of the company’s stock valued at $4,879,289,000 after acquiring an additional 529,974 shares in the last quarter. Alliancebernstein LP increased its holdings in Zoetis by 2.6% during the 4th quarter. Alliancebernstein LP now owns 17,663,325 shares of the company’s stock valued at $4,310,381,000 after acquiring an additional 441,440 shares in the last quarter. Geode Capital Management LLC increased its holdings in Zoetis by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 8,710,236 shares of the company’s stock valued at $2,120,301,000 after acquiring an additional 159,268 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Zoetis by 0.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 5,360,660 shares of the company’s stock worth $1,308,162,000 after buying an additional 24,432 shares in the last quarter. Hedge funds and other institutional investors own 90.73% of the company’s stock.

In other Zoetis news, Director Willie M. Reed sold 1,855 shares of Zoetis stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $162.31, for a total transaction of $301,085.05. Following the transaction, the director now directly owns 6,782 shares of the company’s stock, valued at $1,100,786.42. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Roxanne Lagano sold 2,167 shares of Zoetis stock in a transaction that occurred on Tuesday, April 26th. The shares were sold at an average price of $178.96, for a total transaction of $387,806.32. Following the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at $4,239,025.52. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,356 shares of company stock worth $1,447,341. 0.12% of the stock is currently owned by corporate insiders.

ZTS opened at $174.21 on Tuesday. The company’s 50 day simple moving average is $167.68 and its 200 day simple moving average is $189.19. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.58 and a current ratio of 2.25. Zoetis Inc. has a 1 year low of $154.18 and a 1 year high of $249.27. The stock has a market capitalization of $81.99 billion, a PE ratio of 39.96, a P/E/G ratio of 2.93 and a beta of 0.73.

Zoetis (NYSE:ZTS – Get Rating) last released its earnings results on Thursday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.10. Zoetis had a net margin of 26.27% and a return on equity of 49.62%. The business had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.98 billion. During the same period last year, the company earned $1.26 earnings per share. The company’s quarterly revenue was up 6.9% on a year-over-year basis. As a group, sell-side analysts expect that Zoetis Inc. will post 5.05 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Thursday, July 21st will be given a dividend of $0.325 per share. The ex-dividend date of this dividend is Wednesday, July 20th. This represents a $1.30 dividend on an annualized basis and a yield of 0.75%. Zoetis’s dividend payout ratio (DPR) is 29.82%.

A number of equities research analysts have recently commented on the stock. Citigroup lowered their price target on shares of Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a report on Wednesday, March 9th. Stifel Nicolaus lowered their price target on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a report on Friday, June 24th. The Goldman Sachs Group lowered their price target on shares of Zoetis from $237.00 to $208.00 and set a “buy” rating for the company in a report on Thursday, May 19th. Finally, StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 26th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Moderate Buy” and a consensus target price of $229.75.

Zoetis Profile (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Get Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)



Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Comment